| Date | Title | Description |
| 09.11.2024 | The Pulse of Innovation: A Look at Recent Developments in Scandinavian Companies | In the ever-evolving landscape of business, innovation is the lifeblood that keeps companies thriving. Recent announcements from Scandinavian firms highlight their commitment to growth, safety, and technological advancement. From healthcare... |
| 08.11.2024 | Biosergen publishes interim report for third quarter 2024 | Biosergen publishes interim report for third quarter 2024
Fri, Nov 08, 2024 08:30 CET Report this content
Friday November 8, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the third quarter 2024. T... |
| 07.11.2024 | Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial | Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial
Thu, Nov 07, 2024 08:30 CET Report this content
November 7, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotech... |
| 31.10.2024 | Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections | Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections
Thu, Oct 31, 2024 17:30 CET Report this content
October 31, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotech... |
| 08.10.2024 | Biosergen's Bold Step in the Fight Against Fungal Infections | In the realm of biotechnology, every breakthrough can feel like a lifeline. Biosergen AB, a clinical-stage company, has recently made headlines by completing the enrollment of its first cohort in a proof-of-concept trial for its drug candid... |
| 07.10.2024 | Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial | Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial
Mon, Oct 07, 2024 08:30 CET Report this content
October 7, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for li... |
| 30.08.2024 | Biosergen publishes interim report for second quarter 2024 | Biosergen publishes interim report for second quarter 2024
Fri, Aug 30, 2024 08:15 CET Report this content
Friday, August 30, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the second quarter 2024.... |
| 30.08.2024 | Biosergen have completed treatment of the first patient with BSG005 | Biosergen have completed treatment of the first patient with BSG005
Fri, Aug 30, 2024 08:00 CET Report this content
Friday, August 30, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby announce the completion of treatment of the firs... |
| 12.07.2024 | First Patient in Biosergen Clinical Trial Treating with BSG005 for Life Threatening Fungal Infection | First Patient in Biosergen Clinical Trial Treating with BSG005 for Life Threatening Fungal Infection
Fri, Jul 12, 2024 10:11 CET Report this content
Stockholm, Sweden – July 12, 2024 – Biosergen AB (“Biosergen”) is pleased to announce that ... |
| 14.06.2024 | Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB | Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB
Fri, Jun 14, 2024 12:25 CET Report this content
Today, on June 14, 2024, the annual general meeting was held in Biosergen AB. A summary of the adopted resolutions fol... |
| 12.06.2024 | Biosergen to welcome two new board members based on election at the Annual General Meeting | Biosergen to welcome two new board members based on election at the Annual General Meeting
Wed, Jun 12, 2024 08:15 CET Report this content
Stockholm, Sweden – June 11, 2024 – Based on the change in ownership during successful capital raise ... |
| 11.06.2024 | Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection. | Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection.
Tue, Jun 11, 2024 12:37 CET Report this content
Stockholm, Sweden – June 11, 2024 – Biosergen AB (“Biosergen”) is ple... |
| 31.05.2024 | Biosergen publishes interim report for first quarter 2024 | Biosergen publishes interim report for first quarter 2024
Fri, May 31, 2024 08:30 CET Report this content
Friday, May 31, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the first quarter 2024. The ... |
| 17.05.2024 | Notice of annual general meeting in Biosergen AB | Notice of annual general meeting in Biosergen AB
Fri, May 17, 2024 08:30 CET Report this content
The shareholders of Biosergen AB, Reg. No. 559304-1295, (the “Company”) are invited to attend the annual general meeting to be held on Friday J... |
| 10.05.2024 | Biosergen publishes 2023 annual report | Biosergen publishes 2023 annual report
Fri, May 10, 2024 13:57 CET Report this content
Friday, May 10, 2024: Biosergen AB (“Biosergen” or the “Company”) publishes annual report for the financial year 2023. The annual report is now available... |
| 16.04.2024 | Conversion of paid subscribed units and first day of trading with warrants of series TO3 | Conversion of paid subscribed units and first day of trading with warrants of series TO3
Tue, Apr 16, 2024 08:46 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO T... |
| 26.03.2024 | Biosergen announces the outcome in the rights issue | Biosergen announces the outcome in the rights issue
Tue, Mar 26, 2024 17:00 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES,... |
| 15.03.2024 | Members of the board of directors and management subscribe in ongoing rights issue | Members of the board of directors and management subscribe in ongoing rights issue
Fri, Mar 15, 2024 08:35 CET Report this content
Biosergen AB (publ) (“Biosergen” or the “Company”) announce that members of the board of directors, through a... |
| 05.03.2024 | Biosergen publishes prospectus due to rights issue of units | Biosergen publishes prospectus due to rights issue of units
Tue, Mar 05, 2024 13:39 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAP... |
| 29.02.2024 | Biosergen publishes interim report for fourth quarter 2023 | Biosergen publishes interim report for fourth quarter 2023
Thu, Feb 29, 2024 08:35 CET Report this content
Thursday, February 29, 2024: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the fourth quarter 2... |
| 12.02.2024 | Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection. | Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.
Mon, Feb 12, 2024 13:07 CET Report this content
Stockholm, Sweden – February 12, 2024 – Biosergen AB (“Biosergen” or the “Compa... |
| 30.01.2024 | Notice of Extraordinary general meeting in Biosergen AB | Notice of Extraordinary general meeting in Biosergen AB
Tue, Jan 30, 2024 21:00 CET Report this content
The shareholders of Biosergen AB, Reg. No. 559304-1295, are invited to attend an extraordinary general meeting to be held on Friday 1 Ma... |
| 30.01.2024 | Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan | Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan
Tue, Jan 30, 2024 18:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECT... |
| 12.01.2024 | Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor | Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor
Fri, Jan 12, 2024 09:35 CET Report this content
Stockholm, Sweden – January 12, 2024 – Biosergen AB (“Biosergen” or the “Co... |
| 12.12.2023 | Biosergen’s Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy | Biosergen’s Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy
Tue, Dec 12, 2023 13:45 CET Report this content
Stockholm, Sweden – Dec... |
| 30.11.2023 | Biosergen AB changes Certified Adviser to Carnegie Investment Bank AB (publ) | Biosergen AB changes Certified Adviser to Carnegie Investment Bank AB (publ)
Thu, Nov 30, 2023 08:44 CET Report this content
Biosergen AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB ... |
| 30.11.2023 | Biosergen publishes interim report for third quarter 2023 | Biosergen publishes interim report for third quarter 2023
Thu, Nov 30, 2023 12:04 CET Report this content
Thursday, November 30, 2023: Biosergen AB (“Biosergen” or the “Company”) hereby publishes the interim report for the third quarter 202... |
| 23.10.2023 | Abstract presented at the 11th Trends in Medical Mycology publicly available | Abstract presented at the 11th Trends in Medical Mycology publicly available
Mon, Oct 23, 2023 10:27 CET Report this content
Stockholm, Sweden – October 23, 2023 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotech compan... |
| 25.09.2023 | Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections | Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections
Mon, Sep 25, 2023 07:30 CET Report this content
Stockholm, September 25, 2023: Biosergen AB (Biosergen) and Alkem Laboratories Ltd. (Al... |
| 28.08.2023 | Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million | Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million
Mon, Aug 28, 2023 15:25 CET Report this content
Stockholm, Sweden - August 28, 2023 – Biosergen AB ("Biosergen&quo... |
| 22.08.2023 | The last day of trading in warrants series TO2 in Biosergen AB is today, August 22, 2023 | The last day of trading in warrants series TO2 in Biosergen AB is today, August 22, 2023
Tue, Aug 22, 2023 07:55 CET Report this content
Stockholm, Sweden - August 22, 2023 - Today is the last day of trading in warrants series TO2 in Bioser... |
| 16.08.2023 | Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management | Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management
Wed, Aug 16, 2023 08:25 CET Report this content
Stockholm, Sweden – August 16 – Biosergen AB ("Biosergen" or t... |
| 14.08.2023 | Biosergen publishes interim report for first quarter 2023 | Biosergen publishes interim report for first quarter 2023
Mon, Aug 14, 2023 08:14 CET Report this content
Monday, August 14, 2023: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the second quarter 2023.... |
| 11.08.2023 | The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023 | The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023
Fri, Aug 11, 2023 08:54 CET Report this content
Stockholm, Sweden - August 11, 2023 - Biosergen AB... |
| 11.08.2023 | Biosergen publish financial report for second quarter ahead of schedule. | Biosergen publish financial report for second quarter ahead of schedule.
Fri, Aug 11, 2023 08:43 CET Report this content
Biosergen announces today that the company will publish the quarterly financial report for Q2 2023 ahead of schedule on... |
| 07.08.2023 | Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11) | Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)
Mon, Aug 07, 2023 10:31 CET Report this content
Stockholm, Sweden – August 7, 2023 – Biosergen AB (“Biosergen” or the “Compa... |
| 12.06.2023 | Biosergen will present at Aktiespararnas Småbolagsdagarna June 13, 2023 | Biosergen will present at Aktiespararnas Småbolagsdagarna June 13, 2023
Mon, Jun 12, 2023 08:30 CET Report this content
Biosergens COO Tine Kold Olesen will present the company. The presentation will be i Stockholm June 13 11:45 and can be ... |
| 31.05.2023 | Biosergen publishes interim report for first quarter 2023 | Biosergen publishes interim report for first quarter 2023
Wed, May 31, 2023 19:05 CET Report this content
Wednesday, May 31, 2023: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the first quarter 2023. ... |
| 31.05.2023 | Bulletin from the annual general meeting on 31 May 2023 in Biosergen AB | Bulletin from the annual general meeting on 31 May 2023 in Biosergen AB
Wed, May 31, 2023 17:59 CET Report this content
Today, on May 31, 2023, the annual general meeting was held in Biosergen AB. A summary of the adopted resolutions follow... |
| 10.05.2023 | Biosergen publishes 2022 annual report | Biosergen publishes 2022 annual report
Wed, May 10, 2023 12:20 CET Report this content
Wednesday, May 10, 2022: Biosergen AB (“Biosergen” or the “Company”) hereby announces that the 2022 annual report is available on the company website (ww... |
| 28.04.2023 | Notice of annual general meeting in Biosergen AB | Notice of annual general meeting in Biosergen AB
Fri, Apr 28, 2023 12:01 CET Report this content
The shareholders of Biosergen AB, Reg. No. 559304-1295, are invited to attend the annual general meeting to be held on Wednesday 31 May 2023 at... |
| 31.03.2023 | Biosergen publishes interim report for fourth quarter 2022 | Biosergen publishes interim report for fourth quarter 2022
Fri, Mar 31, 2023 11:17 CET Report this content
Friday, March 31, 2023: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the fourth quarter 2022.... |
| 29.03.2023 | Biosergen provides Phase 2 clinical development strategy update | Biosergen provides Phase 2 clinical development strategy update
Wed, Mar 29, 2023 08:30 CET Report this content
Stockholm, Sweden – March 29, 2023 – Biosergen AB (“Biosergen” or the “Company”), today announced an update of the Company’s Pha... |
| 21.03.2023 | Biosergen will be participating at Mangold Insight Investor Day, March 22 | Biosergen will be participating at Mangold Insight Investor Day, March 22
Tue, Mar 21, 2023 17:20 CET Report this content
https://mangold.se
For further information, please contact:
Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail... |
| 13.03.2023 | Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections. | Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
Mon, Mar 13, 2023 08:32 CET Report this content
March ... |
| 16.01.2023 | Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial | Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial
Mon, Jan 16, 2023 13:35 CET Report this content
January 16, 2023: Biosegen AB (“Biosergen” or the “Company”) today announced that the Safety Review C... |
| 12.12.2022 | The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005 | The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005
Mon, Dec 12, 2022 10:46 CET Report this content
December 12, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that the first volunteer in the... |
| 30.11.2022 | Biosergen publishes interim report for third quarter 2022 | Biosergen publishes interim report for third quarter 2022
Wed, Nov 30, 2022 10:36 CET Report this content
Wednesday, November 30, 2022: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the third quarter 2... |
| 15.09.2022 | The subscription period in Biosergen’s rights issue starts today | The subscription period in Biosergen’s rights issue starts today
Thu, Sep 15, 2022 09:23 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRA... |
| 14.09.2022 | Biosergen AB: Correction regarding ISIN code for unit rights in rights issue | Biosergen AB: Correction regarding ISIN code for unit rights in rights issue
Wed, Sep 14, 2022 15:46 CET Report this content
The ISIN code for unit rights in the forthcoming rights issue that was communicated in the prospectus has been note... |
| 13.09.2022 | Biosergen AB: Biosergen publishes prospectus due to rights issue of units | Biosergen AB: Biosergen publishes prospectus due to rights issue of units
Tue, Sep 13, 2022 12:32 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATE... |
| 08.09.2022 | Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study. | Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study.
Thu, Sep 08, 2022 10:25 CET Report this content
September 8, 2022: Biosegen AB (“B... |
| 02.09.2022 | Biosergen AB: Biosergen’s Board of Directors decides on a rights issue of units of approximately SEK 60.2 million | Biosergen AB: Biosergen’s Board of Directors decides on a rights issue of units of approximately SEK 60.2 million
Fri, Sep 02, 2022 08:20 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR... |
| 31.08.2022 | Biosergen publishes interim report for second quarter 2022 | Biosergen publishes interim report for second quarter 2022
Wed, Aug 31, 2022 08:49 CET Report this content
Wednesday, August 31, 2022: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the second quarter 2... |
| 31.08.2022 | Biosergen receives a loan of SEK 7 million to finance continued development | Biosergen receives a loan of SEK 7 million to finance continued development
Wed, Aug 31, 2022 08:13 CET Report this content
August 31, 2022: Biosergen AB (“Biosergen” or the “Company”) announces that it has entered into a loan agreement of ... |
| 26.08.2022 | Biosergen completes the third cohort of BSG005 phase I trial | Biosergen completes the third cohort of BSG005 phase I trial
Fri, Aug 26, 2022 11:14 CET Report this content
August 26, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that the Safety Review Committee has decided to contin... |
| 11.07.2022 | 3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial. | 3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.
Mon, Jul 11, 2022 10:00 CET Report this content
Mucormycosis is a difficult to treat invasive fung... |
| 30.06.2022 | Biosergen successfully completes second cohort of BSG005 phase I trial | Biosergen successfully completes second cohort of BSG005 phase I trial
Thu, Jun 30, 2022 09:14 CET Report this content
June 30, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that the Safety Review Committee found no safe... |
| 07.06.2022 | Biosergen publishes 2021 Annual report | Biosergen publishes 2021 Annual report
Tue, Jun 07, 2022 10:42 CET Report this content
Biosergen AB (publ) today announced that the Annual report for 2021 is now available on the company’s website.
To download the annual report, follow the ... |
| 31.05.2022 | Biosergen publishes interim report for first quarter 2022 | Biosergen publishes interim report for first quarter 2022
Tue, May 31, 2022 09:00 CET Report this content
Tuesday, May 31, 2022: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the firdst quarter 2022. T... |
| 25.05.2022 | NOTICE OF ANNUAL GENERAL MEETING IN BIOSERGEN AB | NOTICE OF ANNUAL GENERAL MEETING IN BIOSERGEN AB
Wed, May 25, 2022 10:13 CET Report this content
The text in English is an unofficial translation of the Swedish original wording. In the event of differences between the English translation a... |
| 13.05.2022 | Biosergen successfully completes first cohort of BSG005 phase I trial | Biosergen successfully completes first cohort of BSG005 phase I trial
Fri, May 13, 2022 10:58 CET Report this content
May 13, 2022: Biosegen AB (“Biosergen” or the “Company”) today announced that the Safety Review Committee found no safety ... |
| 02.05.2022 | Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus. | Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus.
Mon, May 02, 2022 08:19 CET Report this content
May 2, 2022: Biosergen today announced that it is preparing a Phase II clinical trial of BSG005 agains... |
| 19.04.2022 | The first subjects dosed successfully with no adverse events in the phase I trial of BSG005 | The first subjects dosed successfully with no adverse events in the phase I trial of BSG005
Tue, Apr 19, 2022 08:58 CET Report this content
April 19, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that there were no adver... |
| 07.04.2022 | The first subject has been dosed in the phase I trial of BSG005 | The first subject has been dosed in the phase I trial of BSG005
Thu, Apr 07, 2022 04:44 CET Report this content
April 7, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that the first volunteer has been dosed with the Comp... |
| 31.03.2022 | Biosergen publishes interim report for fourth quarter 2021 | Biosergen publishes interim report for fourth quarter 2021
Thu, Mar 31, 2022 13:17 CET Report this content
Thursday, March 31, 2022: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the fourth quarter 202... |
| 30.11.2021 | Biosergen publishes interim report for the third quarter 2021 | Biosergen publishes interim report for the third quarter 2021 Tue, Nov 30, 2021 08:27 CET
Tuesday, November 30, 2021: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the third quarter 2021. The interim r... |
| 31.08.2021 | Biosergen publishes interim report for the second quarter 2021 | Biosergen publishes interim report for the second quarter 2021 Tue, Aug 31, 2021 08:30 CET
Tuesday, August 31, 2021: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the second quarter 2021. The interim r... |
| 31.08.2021 | Biosergen : publishes interim report for the second quarter 2021 | Tuesday, August 31, 2021: Biosergen AB ("Biosergen" or the "Company") thereby publishes the interim report for the second quarter 2021. The interim report is available as an attached document and on the company website (... |
| 24.08.2021 | Biosergen’s application to start human clinical trials with BSG005 is approved | Biosergen’s application to start human clinical trials with BSG005 is approved Tue, Aug 24, 2021 10:23 CET
Tuesday, August 24, 2021: Biosegen AB (“Biosergen” or the “Company”) today announced that it has received positive feed back from the... |
| 19.08.2021 | Tine Kold Olesen will join Biosergen AB as Chief Operating Officer | Tine Kold Olesen will join Biosergen AB as Chief Operating Officer Thu, Aug 19, 2021 18:51 CET
Thursday, August 19, 2021: Biosergen AB (“Biosergen” or the “Company”) today announced that it has appointed Tine Kold Olesen as COO of Biosergen... |
| 08.06.2021 | BIOSERGEN’S OFFERING IS FULLY SUBSCRIBED | BIOSERGEN’S OFFERING IS FULLY SUBSCRIBED Tue, Jun 08, 2021 16:48 CET
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND,... |
| 31.05.2021 | The outbreak of mucormycosis (the so-called “Black Fungus”) in India is a prime example of the great need for a safer antifungal drug with true fungicidal activity | The outbreak of mucormycosis (the so-called “Black Fungus”) in India is a prime example of the great need for a safer antifungal drug with true fungicidal activity Mon, May 31, 2021 17:22 CET
Monday, May 31, 2021: India is seeing an outbrea... |
| 19.05.2021 | BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM | BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM Wed, May 19, 2021 14:00 CET
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRAL... |